August 19, 2019
This monthly feature presents a variety of questions from clinical trial professionals with answers from WCG Clinical’s expert staff. To ask a question of WCG’s experts, click here: https://bit.ly/2XB9F6R.
We are planning on using a sub-investigator to support a clinical trial at our site. What do we need to include in the contract to ensure that we are compliant with the Florida Sunshine law and the Stark law?Should we explicitly state in the contract that we are compensating the sub-investigator for services and that we are not paying for subject referrals? What is a good compensation for a sub-investigator? — Staff at research site
The Sunshine law in Florida requires that 1) meetings of boards or commissions must be open to the public; 2) reasonable notice of such meetings must be given; and 3) minutes of the meeting must be taken.There is no mention of payments to investigators or sub-investigators.
However, under the Centers for Medicare & Medicaid Services Open Payments Program, there is a national disclosure requirement by making the financial relationships between applicable manufacturers, such as pharmaceutical companies and healthcare providers, available to the public.Under the Open Payments program, you are required to report only the names of principal investigators and not sub-investigators.The report may include up to five principal investigators for each research payment reported.
The Stark law prohibits physicians from referring patients to receive “designated health services” payable by Medicare or Medicaid from entities with which the physician or an immediate family member has a financial relationship, unless an exception applies. Financial relationships include both ownership/investment interests and compensation arrangements.The Stark law is a strict liability statute, which means proof of specific intent to violate the law is not required.Therefore, so long as the sub-investigator does not have any financial interests as stated above and does not make such referrals, he/she is likely to be compliant.
Unfortunately, we cannot comment on the compensation for this sub-investigator.However, it should be noted that all payments for services related to clinical trials must be within fair market value.Some of the considerations that help determine if payments are considered fair market value include:
- Is the payment usual and customary fees for similar services;
- Does the payment reflect the local jurisdiction in which the services are performed; and
- Are the fees defensible when judged against other fees paid to investigators working on the same study?
Please be advised that one of the critical components in scrutinizing payments to investigators and sub-investigators is the division of labor.Paying an investigator and sub-investigator the same amount for the same services is not acceptable. — Marco Capasso, Chief Legal Officer, WCG Clinical